Cwm LLC Cuts Stock Holdings in GSK plc (NYSE:GSK)

Cwm LLC trimmed its stake in shares of GSK plc (NYSE:GSK) by 7.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 184,933 shares of the pharmaceutical company’s stock after selling 14,389 shares during the period. Cwm LLC’s holdings in GSK were worth $7,928,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Versant Capital Management Inc grew its stake in shares of GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 676 shares in the last quarter. BKM Wealth Management LLC purchased a new position in shares of GSK in the 4th quarter worth $32,000. Richardson Financial Services Inc. purchased a new position in shares of GSK in the 4th quarter worth $40,000. Jones Financial Companies Lllp grew its stake in shares of GSK by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after buying an additional 509 shares in the last quarter. Finally, Princeton Global Asset Management LLC grew its stake in shares of GSK by 54.3% in the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after buying an additional 533 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on GSK. The Goldman Sachs Group began coverage on shares of GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price objective for the company. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and an average target price of $47.00.

GSK Price Performance

GSK stock opened at $40.95 on Thursday. The firm has a 50-day moving average price of $42.56 and a 200-day moving average price of $41.03. The firm has a market capitalization of $84.87 billion, a PE ratio of 14.84, a price-to-earnings-growth ratio of 1.24 and a beta of 0.66. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92.

GSK (NYSE:GSK) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The firm had revenue of $9.34 billion during the quarter, compared to analyst estimates of $8.98 billion. As a group, equities research analysts forecast that GSK plc will post 4.11 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a dividend of $0.3762 per share. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a yield of 3.67%. GSK’s dividend payout ratio (DPR) is presently 53.26%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.